CTI BioPharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	4.41	4.14	0.43	-	-
Revenue Growth (YoY)	245.97%	857.04%	-	-	-
Cost of Revenue	2.76	2.54	0.29	-	-
Gross Profit	1.65	1.6	0.14	-	-
Selling, General & Admin	25.69	24.81	15.42	3.83	7.7
Research & Development	4.45	3.14	0.76	1.27	0.12
Operating Expenses	30.14	27.95	16.18	5.1	7.82
Operating Income	-28.49	-26.35	-16.04	-5.1	-7.82
Interest Expense	-0.33	-0.26	-0.12	-	-
Interest & Investment Income	1.74	1.24	0.01	0	0
Currency Exchange Gain (Loss)	0.03	0.07	0.05	-	-
Other Non Operating Income (Expenses)	-6.78	-7.01	-0.19	0.15	-
Pretax Income	-33.83	-32.31	-16.3	-4.95	-7.82
Income Tax Expense	0.09	0.11	-0.01	-	-
Earnings From Continuing Operations	-33.92	-32.42	-16.29	-4.95	-7.82
Minority Interest in Earnings	0.09	0.09	0.01	-	-
Net Income	-33.83	-32.33	-16.29	-4.95	-7.82
Preferred Dividends & Other Adjustments	2.78	2.78	-	-	-
Net Income to Common	-36.61	-35.11	-16.29	-4.95	-7.82
Shares Outstanding (Basic)	62	56	33	27	16
Shares Outstanding (Diluted)	62	56	33	27	16
Shares Change (YoY)	67.66%	68.36%	23.41%	64.92%	-
EPS (Basic)	-0.59	-0.63	-0.49	-0.18	-0.48
EPS (Diluted)	-0.59	-0.63	-0.49	-0.18	-0.48
Free Cash Flow	-29.38	-28.07	-7.74	-7.41	-10.7
Free Cash Flow Per Share	-0.47	-0.50	-0.23	-0.28	-0.66
Gross Margin	37.40%	38.60%	32.09%	-	-
Operating Margin	-646.72%	-635.91%	-3704.63%	-	-
Profit Margin	-831.04%	-847.28%	-3761.03%	-	-
Free Cash Flow Margin	-666.92%	-677.27%	-1788.28%	-	-
EBITDA	-27.97	-25.88	-16	-	-
D&A For EBITDA	0.52	0.47	0.04	-	-
EBIT	-28.49	-26.35	-16.04	-5.1	-7.82
Revenue as Reported	4.14	4.14	0.43	-	-

Updated Mar 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q